Ricevi le ultime notizie sulle azioni BioCardia con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di BCDA

Ultime notizie per

BIOCARDIA INC

BioCardia

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

BioCardia Inc

Health Care

Press Releases

General

BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP® Cell Therapy in Ischemic Heart Failure

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

News

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

Earnings

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D™ Fusion Imaging for Interventional Cardiology

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

Financing

BioCardia Announces Pricing of Up To $12 Million Public Offering

BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure

BioCardia Regains Compliance with Nasdaq Listing Requirements

BCDA

Abpro Hldgs

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

Bio Green Med Solution, Inc. - Common Stock

Bio Green Med Solution

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Geovax Labs

iBio

Imunon

Immuron Limited - American Depositary Shares

Immuron

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics

Longeveron

Mustang Bio

Marker Therapeutics

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NextCure

OSR Holdings

Palisade Bio

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Soligenix

Sensei Biotherapeutics, Inc. - Common Stock

Comments

BioCardia Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO